Adverum Biotechnologies, Inc. ADVM
Set alert
4.36 USD 0.00 0.00%
At close · Dec 9
4.49 +0.13 +2.98%
After hours · Dec 9, 4:00 PM ET
4.24 Day range 4.36
52-week range unavailable
- YTD
- -6.64%
- 1 year
- -26.23%
- Open
- 4.24
- Prev close
- 4.36
- Mkt cap
- 98.60M
- Vol
- 675.98K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.24
- High
- 4.36
- Forward P/E
- -0.89
- Beta
- 1.01
- Short ratio
- 5.53
- Inst. own
- 79.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.82
- 200-d avg
- 8.42
- 1y target
- 29.71
Analyst view
Consensus: none
Price target (mean) 29.71 +581.5% upside
Now 4.36
- Target (low)
- 10.00
- Target (mean)
- 29.71
- Target (high)
- 40.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.39 | -1.74 – -1.05 | -2.30 | +39.8% | 0 | 0.0% | 6 |
| Next quarter | -1.33 | -1.60 – -1.06 | -1.50 | +11.2% | 0 | 0.0% | 4 |
| Current year | -5.04 | -5.41 – -4.62 | -11.60 | +56.6% | 1.00M | -72.2% | 6 |
| Next year | -4.34 | -5.99 – -0.21 | -5.04 | +13.9% | 12.62M | +1161.9% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 5, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Aug 14, 2024 | Truist Securities | Maintained | Buy | Buy |
| Aug 13, 2024 | HC Wainwright& Co. | Reiterated | Buy | Buy |
| Aug 13, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Jul 18, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Jun 25, 2024 | Oppenheimer | Initiated | — | Outperform |
| May 15, 2024 | Truist Securities | Maintained | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 30, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Apr 29, 2024 | Mizuho | Maintained | Buy | Buy |
| Mar 19, 2024 | Chardan Capital | Reiterated | Buy | Buy |
| Mar 19, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Feb 6, 2024 | Mizuho | Maintained | Buy | Buy |
| Nov 2, 2023 | Mizuho | Initiated | — | Buy |
| Sep 5, 2023 | Truist Securities | Reiterated | Buy | Buy |
| Aug 11, 2023 | Chardan Capital | Upgrade | Neutral | Buy |
| Mar 7, 2023 | Ladenburg Thalmann | Initiated | — | Buy |
| Nov 11, 2022 | Chardan Capital | Maintained | — | Neutral |
| Nov 11, 2022 | RBC Capital | Maintained | — | Sector Perform |
| Aug 12, 2022 | Chardan Capital | Maintained | — | Neutral |
| Jul 7, 2022 | Truist Securities | Upgrade | Hold | Buy |
| Jul 23, 2021 | Chardan Capital | Maintained | — | Neutral |
| Jul 23, 2021 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Jul 23, 2021 | SVB Leerink | Maintained | — | Market Perform |
| May 3, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Apr 29, 2021 | Chardan Capital | Downgrade | Buy | Neutral |
| Apr 29, 2021 | Truist Securities | Downgrade | Buy | Hold |
| Apr 29, 2021 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Apr 29, 2021 | SVB Leerink | Maintained | — | Outperform |